Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study of rocbrutinib in generalized myasthenia gravis
ChiCTR2600134949Phase 4Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rocbrutinib in myasthenia gravis (MG), sponsored by Beijing Tiantan Hospital. Primary endpoints: Safety and Quantitative Myasthenia Gravis score. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
rocbrutinib
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2600134949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134949.